<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22731">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02810873</url>
  </required_header>
  <id_info>
    <org_study_id>08F.327</org_study_id>
    <nct_id>NCT02810873</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer</brief_title>
  <official_title>PET Imaging of Breast Cancer Using Oncogene Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies positron emission tomography imaging in using copper Cu 64
      TP3805in patients with breast cancer. Diagnostic procedures, such as positron emission
      tomography (PET) and positron emission mammography (PEM) scan, using Cu-64-TP3805 may help
      doctors find and diagnose breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      I. The study's primary goal is to assess the ability of Cu-64-TP3805 (copper Cu 64 TP3805)
      to detect primary breast lesions as determined by the F-18-FDG (fludeoxyglucose F 18) scan.

      II. The study's second goal is to determine the ability of Cu-64-TP3805 to detect primary
      breast lesions as determined by histology (sensitivity).

      III. The study's third goal is to determine the ability of Cu-64-TP3805 to detect metastatic
      lesions as identified by the F-18-FDG whole-body scan.

      OUTLINE: This is a dose-finding 2-stage study.

      STAGE I: Patients with a positive biopsy and abnormal (positive) fludeoxyglucose F18-labeled
      PET whole-body scan undergo a whole-body copper Cu 64 TP3805-labeled PET scan.

      STAGE II: Patients with a positive biopsy, but no fludeoxyglucose F18 scan undergo a breast
      fludeoxyglucose F18-labeled PEM scan followed by a breast copper Cu 64 TP3805-labeled PEM
      scan.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated by PI
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of F-18-FDG positive lesions that are detected by the copper Cu 64 TP3805 analog</measure>
    <time_frame>4 hours after Cu 64 TP3805 administered</time_frame>
    <description>Cu-64 results will be compared with those of F-18-FDG for: i) imaging number and size of the primary lesions; ii) imaging distant metastases, if any (stage-1 patients only); iii) imaging involved lymph nodes. The unit of analysis will be the lesion (with potentially multiple lesions available per patient). The study follows a 2-stage design. 95% confidence intervals will be used. To account for the multiplicity of lesions per patient, the Generalized Estimating Equations (GEE) approach will be used, with the robust variance. Any adverse events will be summarized descriptively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ability of copper Cu 64 TP3805to detect primary breast lesions as determined by histology (sensitivity)</measure>
    <time_frame>4 hours after Cu 64 TP3805 administered</time_frame>
    <description>Optimal imaging time is the one (of the three) which will have least background activity in the surrounding tissue and image the maximum number of lesions with clarity. 95% confidence intervals will be used. To account for the multiplicity of lesions per patient, the GEE approach will be used, with the robust variance. Any adverse events will be summarized descriptively.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic Positron Emission Tomography, (PET)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STAGE I: Patients with a positive biopsy and abnormal (positive) fludeoxyglucose F18-labeled PET whole-body scan undergo a whole-body copper Cu 64 TP3805-labeled PET scan.
STAGE II: Patients with a positive biopsy, but no fludeoxyglucose F18 scan undergo a breast fludeoxyglucose F18-labeled PEM Positron Emission Mammography scan followed by a breast copper Cu 64 TP3805-labeled PEM scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Positron Emission Mammography</intervention_name>
    <description>Undergo PEM Positron Emission Mammography scan</description>
    <arm_group_label>Diagnostic Positron Emission Tomography, (PET)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET Positron Emission Tomography scan</description>
    <arm_group_label>Diagnostic Positron Emission Tomography, (PET)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Fludeoxyglucose F-18</intervention_name>
    <description>Undergo Fludeoxyglucose F-18 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan</description>
    <arm_group_label>Diagnostic Positron Emission Tomography, (PET)</arm_group_label>
    <other_name>2-Deoxy-2-(18F)Fluoro-D-Glucose</other_name>
    <other_name>2-F18-Fluoro-2-deoxy-D-glucose</other_name>
    <other_name>2-F18-Fluoro-2-deoxyglucose</other_name>
    <other_name>105851-17-0</other_name>
    <other_name>18FDG</other_name>
    <other_name>723398</other_name>
    <other_name>FDG</other_name>
    <other_name>Fluorine-18 2-Fluoro-2-deoxy-D-Glucose</other_name>
    <other_name>Fluorodeoxyglucose F18</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copper Cu 64 TP3805</intervention_name>
    <description>Undergo copper Cu 64 TP3805 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan</description>
    <arm_group_label>Diagnostic Positron Emission Tomography, (PET)</arm_group_label>
    <other_name>Cu-64-TP3805</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  Breast cancer shown with abnormal mammogram and histology verification (stage-1
             patients will also need to have a positive F-18-FDG whole-body scan)

          -  Tumor mass of 1 cm or larger, as determined by mammography, ultrasound, or magnetic
             resonance imaging (MRI)

          -  Signed informed consent form approved by the institutional review board (IRB)

        Exclusion Criteria:

          -  Pregnant or lactating female

          -  Patient with asthma
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madhukar Thakur, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <link>
    <url>http://hospitals.jefferson.edu/</url>
    <description>Thomas Jefferson University Hospital</description>
  </link>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 18, 2016</lastchanged_date>
  <firstreceived_date>June 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Deoxyglucose</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
    <mesh_term>Copper</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
